About ruxolitinib phosphate
JAK1/JAK2 inhibitor
Used for
- Myelofibrosis
- Polycythemia vera after inadequate response to hydroxyurea
- Graft-versus-host disease in certain patients
Usual adult dose
Myelofibrosis: usually 5–20 mg twice daily, adjusted by blood counts. Polycythemia vera: usually 10 mg twice daily. Graft-versus-host disease: usually 5 mg twice daily, adjusted as needed.
Usual dose in children
Graft-versus-host disease: children aged 12 years and older generally receive adult dosing; younger children require specialist dosing.
Common side effects
- Low blood counts, including anemia, low platelets, or low white cells
- Bruising or bleeding
- Infections, including shingles
- Dizziness or headache
Important warnings
- Blood counts need monitoring; severe cytopenias can occur.
- Serious infections and certain cancers have been reported.
- Stopping suddenly may worsen symptoms; dose changes require medical supervision.
- Dose adjustments may be needed for liver or kidney problems.
Pregnancy
May harm an unborn baby; pregnancy use requires careful clinician assessment.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the final dose.
Interactions
- Strong CYP3A4 inhibitors, such as ketoconazole, can raise drug levels.
- Rifampin and other strong CYP3A4 inducers can lower drug levels.
- Other immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.